上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 综述 • 上一篇    下一篇

抗血小板治疗新靶点：糖蛋白Ⅵ

陈一竹，张俊峰   

  1. CHEN Yi-zhu, ZHANG Jun-feng
  • 出版日期:2015-07-28 发布日期:2015-08-27
  • 作者简介:陈一竹（1988—）， 女， 硕士生; 电子信箱: yuhuzhujun@163.com。
  • 基金资助:

    上海申康适宜技术推广项目（SHDC12012210）；宝山区科委项目（12-E-63）

A new target of antiplatelet therapy: glycoprotein Ⅵ

上海交通大学 医学院附属第三人民医院心内科， 上海 201999   

  1. Department of Cardiology, Shanghai Third People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, China
  • Online:2015-07-28 Published:2015-08-27
  • Supported by:

    Shanghai Shen-Kang Technique Expansion Project, SHDC12012210; Baoshan District Science and Technology Commission Project, 12-E-63

PDF (PC)

1513

摘要：

抗血小板治疗在心血管疾病的治疗中占重要地位，目前临床上可应用的药物有多种，但其疗效并不令人满意，主要存在出血等并发症，所以迫切需要找到既高效又安全的新型药物。糖蛋白Ⅵ（GPⅥ）是血小板膜上众多受体之一，也是目前寻找抗血栓药物的新方向。该文就GPⅥ相关内容作一综述。

关键词: 糖蛋白Ⅵ, 血小板, 动脉粥样硬化

Abstract:

Antiplatelet therapy plays a significant role in the treatment of cardiovascular disease. Now there are many drugs available for clinical application, but the curative effect is unsatisfactory. Complications such as bleeding are major problems. So it is urgent to find efficient and safe new drugs. Glycoprotein Ⅵ (GP Ⅵ) is one of the many receptors on platelet membrane and is also a new direction for developing antithrombotic drugs. This paper reviews studies relevant to GP Ⅵ.

Key words: glycoprotein Ⅵ, platelet, artery atherosclerotic